



MITHRA ANNOUNCES INJECTABLE CONTRACT WITH MIDAS PHARMA

- **Mithra closes contract with Midas Pharma for development and potential manufacturing of sterile injectable**
- **Strong validation by reputable partner of know-how and capabilities of Mithra CDMO**

Liège, Belgium, 16 May 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women's Health, today announces a contract with Midas Pharma for the development of a sterile injectable product at the Mithra CDMO¹. Midas Pharma, based in Germany, is a full-service provider and a leader in the sourcing and supplying of intermediates, APIs (Active Pharmaceutical Ingredients), FDFs (Finished Dosage Forms) and dossiers for finished products. The company is present in 10 countries and works with generic pharma players, big pharma companies as well as biotech firms.

Financial terms of the contract were not disclosed. Following the umbrella agreement signed with GSP in 2017, this new contract with a highly regarded partner in the field is a further endorsement of the Mithra CDMO.

François Fornieri, CEO of Mithra, commented: *"We are very pleased to announce another contract for the injectable section of our Mithra CDMO with a well-known and highly regarded player in the field, and we are looking forward to working with the Midas team on the development as well as the potential manufacturing and supply of the injectable product. The agreements with GSP and Midas underline the confidence of these partners in the Mithra CDMO, and may position us well for future partnering discussions."*

For more information, please contact:

Investor Relations

Sofie Van Gijssels, IRO

+32 485 19 14 15

investorrelations@mithra.com

svangijssels@mithra.com

About Midas Pharma

Midas Pharma GmbH, which has its head office in Ingelheim am Rhein (Germany), employs more than 180 staff in 10 countries around the world. Ever since the company was founded in 1988, research-based pharmaceutical companies and generics companies have relied on Midas' products and services. The company is a reputable player in the market thanks to its high-quality staff and its comprehensive service and product portfolio.

¹ Contract Development & Manufacturing Organization

Midas implements development and sales projects in its two major business areas of active ingredients and finished products. The company has a unique approach to identify market needs and form individual project alliances with partners, each of which bring their own strengths. As a result, Midas covers the entire pharmaceutical, non-clinical value chain – from active ingredient synthesis to marketing authorization for the finished product. Midas does not have its own laboratories or production, and uses its global presence and networks to combine the most suitable partners and best infrastructure for each project.

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO. Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com